BioCentury
ARTICLE | Clinical News

V419: Phase III started

May 2, 2011 7:00 AM UTC

Merck and sanofi-aventis' Sanofi Pasteur S.A. vaccines unit began an open-label, international Phase III trial in about 1,440 infants to evaluate 0.5 mL intramuscular V419. Subjects will receive V419 at 2, 4, 6 and 15 months of age and PedvaxHib at 15 months. Subjects in the comparator arm will receive Pentacel at 2, 4 and 6 months of age, a modified process hepatitis B vaccine at 2 and 6 months and ActHib at 15 months. Both arms will receive Prevnar 13 at 2, 4, 6 and 15 months of age, RotaTeq at 2, 4 and 6 months and Daptacel at 15 months. Merck and the vaccines unit are jointly developing V419. ...